These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18433053)

  • 1. Reply: Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
    Huprikar S
    Liver Transpl; 2008 May; 14(5):709. PubMed ID: 18433053
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
    Reed A; Herndon JB; Ersoz N; Fujikawa T; Schain D; Lipori P; Hemming A; Li Q; Shenkman E; Vogel B
    Liver Transpl; 2007 Dec; 13(12):1743-50. PubMed ID: 18044769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
    Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
    Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
    Shah T; Lai WK; Gow P; Leeming J; Mutimer D
    Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and treatment of fungal infections in solid-organ transplant recipients].
    Muñoz P; Bouza E
    Rev Clin Esp; 1995 Oct; 195 Suppl 3():38-48. PubMed ID: 9441304
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
    Hellinger WC; Bonatti H; Yao JD; Alvarez S; Brumble LM; Keating MR; Mendez JC; Kramer DJ; Dickson RC; Harnois DM; Spivey JR; Hughes CB; Nguyen JH; Steers JL
    Liver Transpl; 2005 Jun; 11(6):656-62. PubMed ID: 15915482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study.
    Biancofiore G; Bindi ML; Baldassarri R; Romanelli AM; Catalano G; Filipponi F; Vagelli A; Mosca F
    Transpl Int; 2002 Jul; 15(7):341-7. PubMed ID: 12122510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.
    Perfect JR; Dodds Ashley E; Drew R
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S207-10. PubMed ID: 15546119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
    Schneemann M; Bachli EB
    Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
    [No Abstract]   [Full Text] [Related]  

  • 10. [Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients].
    López-Medrano F; Díaz-Pedroche C; Lumbreras C; Aguado JM
    Rev Esp Quimioter; 2005 Mar; 18(1):14-20. PubMed ID: 15915227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trichosporon asahii fatal infection in a non-neutropenic patient after orthotopic liver transplantation.
    Abdala E; Lopes RI; Chaves CN; Heins-Vaccari EM; Shikanai-Yasuda MA
    Transpl Infect Dis; 2005; 7(3-4):162-5. PubMed ID: 16390408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B for fever and neutropenia.
    Winston DJ; Schiller GJ; Territo MC
    N Engl J Med; 1999 Oct; 341(15):1154-5. PubMed ID: 10515755
    [No Abstract]   [Full Text] [Related]  

  • 13. Liposomal amphotericin B for fever and neutropenia.
    Rakita R
    N Engl J Med; 1999 Oct; 341(15):1153-4; author reply 1154-5. PubMed ID: 10515754
    [No Abstract]   [Full Text] [Related]  

  • 14. Amphotericin B: is a lipid-formulation gold standard feasible?
    Spellberg B; Witt MD; Beck CK
    Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470
    [No Abstract]   [Full Text] [Related]  

  • 15. Fusarium infection after solid-organ transplantation.
    Sampathkumar P; Paya CV
    Clin Infect Dis; 2001 Apr; 32(8):1237-40. PubMed ID: 11283817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections.
    Stewart A; Powles R; Hewetson M; Antrum J; Richardson C; Mehta J
    Pharmacoeconomics; 1995 Oct; 8(4):350-61. PubMed ID: 10155676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients.
    Penack O; Reinhold T; Thiel E; Blau IW
    Onkologie; 2007 Dec; 30(12):621-6. PubMed ID: 18063874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effective use of liposomal amphotericin B.
    O'Connell B; Craig JI; Marcus RE; Ludlam H
    Clin Lab Haematol; 2002 Oct; 24(5):317-9. PubMed ID: 12358895
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients.
    Fortún J; Martín-Dávila P; Montejo M; Muñoz P; Cisneros JM; Ramos A; Aragón C; Blanes M; San Juan R; Gavaldá J; Llinares P;
    Transplantation; 2009 Feb; 87(3):424-35. PubMed ID: 19202450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.